IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Tarsus Prescribed drugs, Inc. (NASDAQ: TARS), whose mission is to concentrate on unmet wants and apply confirmed science and new expertise to revolutionize therapy for sufferers, beginning with eye care, at present introduced that it’ll host a reside webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 monetary outcomes and supply a company replace.
Individuals might entry the webcast right here. A recorded model of the decision might be obtainable on the web site shortly after the completion of the webcast and might be archived there for roughly 90 days.
About Tarsus Prescribed drugs, Inc.
Tarsus Prescribed drugs, Inc. applies confirmed science and new expertise to revolutionize therapy for sufferers, beginning with eye care. Tarsus is advancing its pipeline to handle a number of ailments with excessive unmet want throughout a variety of therapeutic classes, together with eye care, dermatology and infectious illness prevention. XDEMVY ® (lotilaner ophthalmic resolution) 0.25% is FDA authorised in the USA for the therapy of Demodex blepharitis. Tarsus can be creating TP-03 as an investigational remedy for the therapy of Meibomian Gland Illness, TP-04 for the therapy of rosacea and TP-05 as an oral pill for the prevention of Lyme illness, all of that are in Part 2.
Media Contact:
Adrienne Kemp
Sr. Director, Company Communications
(949) 922-0801
akemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
